open access

Vol 70, No 6 (2019)
Original paper
Submitted: 2019-06-15
Accepted: 2019-07-29
Early publication date: 2019-11-19
Get Citation

The efficacy of pharmacotherapy in postmenopausal osteoporosis: a longitudinal observational study

Wojciech Pluskiewicz1, Piotr Adamczyk2, Edward Franek3, Ewa Sewerynek4, Hanna Wichrowska5, Luiza Napiórkowska5, Michał Stuss4, Aleksandra Rozwandowicz4, Bogna Drozdzowska6
DOI: 10.5603/EP.a2019.0058
·
Pubmed: 31909456
·
Endokrynol Pol 2019;70(6):473-477.
Affiliations
  1. Department and Clinic of Internal Diseases, Diabetology, and Nephrology, Metabolic Bone Diseases Unit, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  2. Department of Paediatrics, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland
  3. Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
  4. Department of Endocrine Disorders and Bone Metabolism, Medical University of Łódź, Poland
  5. Department of Internal Diseases, Endocrinology, and Diabetology, Central Clinical Hospital MSWiA, Warsaw, Poland
  6. Department and Chair of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

open access

Vol 70, No 6 (2019)
Original Paper
Submitted: 2019-06-15
Accepted: 2019-07-29
Early publication date: 2019-11-19

Abstract

Introduction: The aim of the study was an assessment of longitudinal changes in fracture probability in postmenopausal women.

Material and methods: A group of 226 postmenopausal women at baseline mean age 66.46 ± 7.96 years were studied. There were 21 women without therapy, 102 taking calcium + vitamin D, and 103 women on antiresorptive therapy, in the study group. Data concerning clinical risk factors for osteoporosis and hip BMD were gathered. Fracture probability for major and hip fractures was established using FRAXTM.

Results: Mean follow-up time was 2.43 ± 0.59 years. Baseline FRAX value in the whole group for major fracture was 7.1 ± 4.18, and at follow-up it was 7.44 ± 4.04. Respective results for FRAX for hip fracture were 3.17 ± 2.69 and 3.02 ± 2.35. In the whole group the probability for major fractures significantly increased during follow-up (p < 0.05) and for hip fracture did not change. In non-treated patients and patients taking calcium + vitamin D the fracture probability increased significantly. In patients on antiresorptive therapy the fracture probability did not change, which was connected with an improvement in bone status assessed by DXA. Femoral neck T-score in the whole group did not change, in those not treated and taking calcium + vitamin D it decreased significantly (p < 0.05), while in treated women it increased significantly (p < 0.05). In patients with improved bone status the FRAX values for major and hip fractures decreased by 0.44 ± 1.62 and 0.36 ± 1.19, respectively. Conversely, in patients with worsening T-score value the FRAX values increased by 1.33 ± 1.42 and 0.66 ± 1.25, respectively.

Conclusion: Antiresorptive therapy stabilises fracture probability in postmenopausal women due to improvement in bone status.

Abstract

Introduction: The aim of the study was an assessment of longitudinal changes in fracture probability in postmenopausal women.

Material and methods: A group of 226 postmenopausal women at baseline mean age 66.46 ± 7.96 years were studied. There were 21 women without therapy, 102 taking calcium + vitamin D, and 103 women on antiresorptive therapy, in the study group. Data concerning clinical risk factors for osteoporosis and hip BMD were gathered. Fracture probability for major and hip fractures was established using FRAXTM.

Results: Mean follow-up time was 2.43 ± 0.59 years. Baseline FRAX value in the whole group for major fracture was 7.1 ± 4.18, and at follow-up it was 7.44 ± 4.04. Respective results for FRAX for hip fracture were 3.17 ± 2.69 and 3.02 ± 2.35. In the whole group the probability for major fractures significantly increased during follow-up (p < 0.05) and for hip fracture did not change. In non-treated patients and patients taking calcium + vitamin D the fracture probability increased significantly. In patients on antiresorptive therapy the fracture probability did not change, which was connected with an improvement in bone status assessed by DXA. Femoral neck T-score in the whole group did not change, in those not treated and taking calcium + vitamin D it decreased significantly (p < 0.05), while in treated women it increased significantly (p < 0.05). In patients with improved bone status the FRAX values for major and hip fractures decreased by 0.44 ± 1.62 and 0.36 ± 1.19, respectively. Conversely, in patients with worsening T-score value the FRAX values increased by 1.33 ± 1.42 and 0.66 ± 1.25, respectively.

Conclusion: Antiresorptive therapy stabilises fracture probability in postmenopausal women due to improvement in bone status.

Get Citation

Keywords

antiresorptive therapy; bone status; follow-up; fracture probability; postmenopausal women

About this article
Title

The efficacy of pharmacotherapy in postmenopausal osteoporosis: a longitudinal observational study

Journal

Endokrynologia Polska

Issue

Vol 70, No 6 (2019)

Article type

Original paper

Pages

473-477

Early publication date

2019-11-19

Page views

1431

Article views/downloads

774

DOI

10.5603/EP.a2019.0058

Pubmed

31909456

Bibliographic record

Endokrynol Pol 2019;70(6):473-477.

Keywords

antiresorptive therapy
bone status
follow-up
fracture probability
postmenopausal women

Authors

Wojciech Pluskiewicz
Piotr Adamczyk
Edward Franek
Ewa Sewerynek
Hanna Wichrowska
Luiza Napiórkowska
Michał Stuss
Aleksandra Rozwandowicz
Bogna Drozdzowska

References (13)
  1. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4): 385–397.
  2. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016. Endocr Pract. 2016; 22(Suppl 4): 1–42.
  3. Marcinkowska M, Ignaszak-Szczepaniak M, Wawrzyniak A, et al. A discussion of the intervention thresholds in osteoporosis treatment in Poland. Endokrynol Pol. 2011; 62(1): 30–36.
  4. Franek E, Wichrowska H, Gozdowski D, et al. WHO fracture risk calculator (FRAX) in the assessment of obese patients with osteoporosis. Endokrynol Pol. 2009; 60(2): 82–87.
  5. Lorenc RS, Głuszko P, Karczmarewicz E, et al. [Diagnostic and therapeutic recommendations in osteoporosis] (in Polish). Medycyna Praktyczna Reumatologia. 2013; 1(special issue): 1–44.
  6. Lorenc R, Głuszko P, Franek E, et al. Guidelines for the diagnosis and management of osteoporosis in Poland : Update 2017. Endokrynol Pol. 2017; 68(5): 604–609.
  7. Pluskiewicz W, Drozdzowska B, Adamczyk P. Ten-year fracture risk in the assessment of osteoporosis management efficacy in postmenopausal women: a pilot study. Climacteric. 2013; 16(1): 117–126.
  8. Leslie WD, Majumdar SR, Lix LM, et al. Can change in FRAX score be used to "treat to target"? A population‐based cohort study. J Bone Miner Res. 2014; 29(5): 1074–1080.
  9. Tamaki J, Iki M, Kadowaki E, et al. Fracture risk prediction using FRAX®: a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study. Osteoporos Int. 2011; 22(12): 3037–3045.
  10. Rubin KH, Abrahamsen Bo, Friis-Holmberg T, et al. Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. Bone. 2013; 56(1): 16–22.
  11. Li G, Thabane L, Papaioannou A, et al. Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures. Bone. 2015; 77: 107–114.
  12. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009; 339: b4229.
  13. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ. 2011; 342: d3651.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl